Literature DB >> 14615843

[Surgery of primary malignant bone tumors].

S Flege1, M Kuhlen, M Paulussen, S Bielack, H Jürgens.   

Abstract

The term primary malignant bone tumors covers a diversity of entities. Tumor resection is preferable in most. In some, surgery alone is sufficient, in others therapy will be based on a combined modality concept. Resection plays the essential role in those tumors treated by surgery alone, e.g., primary osseous fibrosarcoma. The combined modality approach in osteosarcomas or Ewing's tumors provides for additional elements of local therapy (radiotherapy) or systemic treatment (chemotherapy). The relevance of surgery for local control varies in these latter diagnoses. In highly malignant osteosarcoma, where wide margin surgery is of utmost importance, only 10-20% of patients will survive longer than 5 years without aggressive systemic chemotherapy. Radiotherapy in these patients is only indicated when "marginal" or "less than marginal" surgery is expected. In terms of efficacy, radiotherapy is inferior to surgery. In disseminated osteosarcoma, a curative treatment approach will also provide for surgical removal of all metastases. Treatment of primary malignant fibrous histiocytoma (MFH) of bone is identical to osteosarcoma therapy. Since radiotherapy appears to be marginally more effective than in osteosarcoma, both modalities of local therapy are used. Systemic chemotherapy adds an additional benefit for improved survival. Therapy for Ewing's tumor also follows a combined modality approach. The introduction of systemic chemotherapy has raised 5-year survival rates from less than 10% to above 60%. The role of surgery is currently subject to debate. At present, the use of surgery or irradiation for local control is tailored to the individual patient's needs.

Entities:  

Mesh:

Year:  2003        PMID: 14615843     DOI: 10.1007/s00132-003-0555-6

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  35 in total

1.  Radiotherapy in Ewing's sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92.

Authors:  A Schuck; J Hofmann; C Rübe; A Hillmann; S Ahrens; M Paulussen; H Jürgens; J Dunst; N Willich
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-12-01       Impact factor: 7.038

2.  Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999.

Authors:  Carlos Rodriguez-Galindo; Catherine A Billups; Larry E Kun; Bhaskar N Rao; Charles B Pratt; Thomas E Merchant; Victor M Santana; Alberto S Pappo
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

3.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

4.  Nonmetastatic pelvic Ewing sarcoma: report of the French society of pediatric oncology.

Authors:  C Carrie; E Mascard; F Gomez; J L Habrand; C Alapetite; O Oberlin; V Moncho; S Hoffstetter
Journal:  Med Pediatr Oncol       Date:  1999-11

5.  The role of surgical therapy in patients with nonmetastatic Ewing's sarcoma of the limbs.

Authors:  A Toni; J R Neff; A Sudanese; D Ciaroni; G Bacci; P Picci; E Barbieri; M Campanacci; A Giunti
Journal:  Clin Orthop Relat Res       Date:  1993-01       Impact factor: 4.176

6.  Malignant fibrous histiocytoma of bone: a retrospective EMSOS study of 125 cases. European Musculo-Skeletal Oncology Society.

Authors:  S S Bielack; A Schroeders; N Fuchs; G Bacci; H C Bauer; S Mapeli; B Tomeno; K Winkler
Journal:  Acta Orthop Scand       Date:  1999-08

7.  Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma.

Authors:  M Sluga; R Windhager; S Lang; H Heinzl; S Bielack; R Kotz
Journal:  Clin Orthop Relat Res       Date:  1999-01       Impact factor: 4.176

8.  Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience.

Authors:  D B Glasser; J M Lane; A G Huvos; R C Marcove; G Rosen
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

9.  [Surgery versus radiotherapy in Ewing's sarcoma with good prognosis. Analysis of the CESS-86 data].

Authors:  J Dunst; C Hoffmann; S Ahrens; H Jürgens
Journal:  Strahlenther Onkol       Date:  1996-05       Impact factor: 3.621

10.  Neoadjuvant chemotherapy for localized Ewing's sarcoma of the extremities: preliminary results of a protocol which uses surgery (alone or followed by radiotherapy) for local control.

Authors:  G Bacci; D Dallari; D McDonald; M Avella; A Toni; E Barbieri; D Ciaroni; A Sudanese; A Mancini; A Giunti
Journal:  Tumori       Date:  1989-10-31
View more
  3 in total

Review 1.  [Extracorporeal irradiation : Reimplantation of bone segments in the treatment of malignant bone tumours].

Authors:  A H Krieg
Journal:  Orthopade       Date:  2017-08       Impact factor: 1.087

2.  Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.

Authors:  Claudia Blattmann; Susanne Oertel; Daniela Schulz-Ertner; Stefan Rieken; Sabine Haufe; Volker Ewerbeck; Andreas Unterberg; Irini Karapanagiotou-Schenkel; Stephanie E Combs; Anna Nikoghosyan; Marc Bischof; Oliver Jäkel; Peter Huber; Andreas E Kulozik; Jürgen Debus
Journal:  BMC Cancer       Date:  2010-03-12       Impact factor: 4.430

3.  Biopsy of tumors of the musculoskeletal system.

Authors:  Jürgen Bruns; Günter Delling; Doris Henne-Bruns; Dieter K Hossfeld
Journal:  Dtsch Arztebl Int       Date:  2008-07-04       Impact factor: 5.594

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.